Technology
Health
Pharmaceutical

Checkpoint Therapeutics

$2.82
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.12 (-4.08%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell CKPT and other stocks, options, ETFs, and crypto commission-free!

About

Checkpoint Therapeutics, Inc. Common Stock, also called Checkpoint Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Read More Its product portfolio include CK-301, CK-101, CK-103, and CK-302. The company was founded on November 10, 2014 and is headquartered in New York, NY.

Employees
7
Headquarters
New York, New York
Founded
2014
Market Cap
100.18M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
80.26K
High Today
$3.20
Low Today
$2.80
Open Price
$2.92
Volume
70.42K
52 Week High
$5.11
52 Week Low
$1.50

Collections

Technology
Health
Pharmaceutical
Medical
Therapy
Biopharmaceutical
Cancer Prevention
2017 IPO

News

Markets InsiderMar 15

Checkpoint Therapeutics Reports Full-Year 2018 Financial Results and Recent Corporate Highlights

NEW YORK, March 15, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced financial results and recent corporate highlights for the full year ended December 31, 2018. James F. Oliviero, President and Chief Executive Officer of Checkpoint, said, “During 2018, we continued to advan...

13
Simply Wall StMar 12

Do Insiders Own Shares In Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)?

The big shareholder groups in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) have power over the company. Institutions often own shares in more established companies, while it’s not unusual to see insiders own a fair bit of smaller companies. Warren Buffett said that he likes ‘a business with enduring competitive advantages that is run by able and owner-oriented people’. So it’s nice to see some insider ownership, because it may suggest that management is owner-oriented. Checkpoint Therapeutics is not a large...

16

Earnings

-$0.38
-$0.33
-$0.28
-$0.23
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.30 per share
Actual
-$0.38 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.